Heterocyclylamines as PI3K inhibitors

A compound of Formula VIIa:

• or a pharmaceutically acceptable salt thereof, wherein:
• G is NH, n is 0, and V is O;
• R1 is C1-3 alkyl;
• R2 is halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, or 5-6 membered heteroaryl;
• wherein said phenyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, OH, CN, C1-4 alkyl, C1-4 alkoxy, and C1-4 haloalkoxy;
• R4 is H, halo, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
• R5 is halo, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, or cyclopropyl;
• R6 is H, halo, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
• R8 is H, halo, —OH, —CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cy2, —(C1-3 alkylene)-Cy2, ORa2, SRa2, C(═O)Rb2, C(═O)NRc2Rd2, C(═O)ORa2, OC(═O)Rb2, OC(═O)NRc2Rd2, NRc2Rd2, NRc2C(═O)Rb2, NRc2C(═O)ORb2, NRc2C(═O)NRc2Rd2, C(═NRe)Rb2, C(═NRe)NRc2Rd2, NRc2C(═NRe)NRc2Rd2, NRc2S(═O)Rb2, NRc2S(═O)2NRc2Rd2, S(═O)Rb2, S(═O)2Rb2, or S(═O)2NRc2Rd2;
• wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R11 groups;
• R10 is H or C1-4 alkyl;
• each Re is independently selected from H, CN, OH, C1-4 alkyl, and C1-4 alkoxy;
• each Cy2 is independently selected from C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, or 9-10-membered bicyclic heteroaryl, each of which is optionally substituted with 1, 2, 3, or 4 independently selected R11 groups;
• each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl;
• wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R11 groups;
• or Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with —OH or C1-3 alkyl;
• and
• each R11 is independently selected from OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO—C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-7 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino.